Exclusive Summary

• Significant Opioid-Sparing Effect: Clinically proven to reduce 24-hour post-operative morphine consumption by 36.8%, perfectly aligning with the global ERAS (Enhanced Recovery After Surgery) protocols and the non-opioid movement.
• Breakthrough Gastrointestinal Safety: Demonstrated a statistically significant 25% reduction in gastrointestinal adverse events compared to control in meta-analyses, overcoming a major safety bottleneck of traditional NSAIDs.
• Clean Formulation and High Compliance: The innovative water-soluble formulation uses only sodium carbonate and water as excipients, eliminating excipient-related risks and ensuring seamless compatibility with PCA pump co-medications.
• Favorable for Special Populations & Low DDI: Exerts weak effects on hepatic enzymes (CYP2C9 metabolism) enabling safe concomitant medication, requiring no dose adjustments for the elderly or patients with mild-to-moderate hepatic/renal impairment.
• De-risked Asset with Clear Global Path: Already approved by China's NMPA, the FDA application was submitted in early 2026, offering global partners a validated, high-value asset for hospital pain and anesthesia portfolios.

Asset Materials

Contact Us for Full Materials